Compare AstraZeneca plc (AZN) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Msci Inc — how do they compare? AstraZeneca plc trades at $158 (market cap $248.14B), while Msci Inc trades at $559.94 (market cap $40.84B). The key difference: AstraZeneca plc is far larger — about 6.1× Msci Inc's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | MSCI | |
|---|---|---|
Market Cap | $248.14B | $40.84B |
Sector | Health | Financials |
52-Week High | $209.48 | $643.83 |
52-Week Low | $147.06 | $511.84 |
Enterprise Value | $275.41B | $47.00B |
Dividend Yield | 2.01% | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
MSCI trades at $562.00, down 0.19% in the last 24 hours, with a bearish technical signal from moving averages but oversold RSI hints at potential rebound. The company reported Q2 2026 EPS of $4.94, slightly missing the $4.99 estimate, yet revenue growth remains robust, with 2025 revenue at $3.13 billion and net income margin of 40.73%. Recent acquisitions like First Street and partnerships with UBS aim to expand its private markets analytics platform, supporting long-term growth.
Outlook is positive with a consensus price target of $728.14, implying 30% upside, driven by strong recurring revenue and high client retention. Risks include elevated debt levels of $4.51 billion and competitive pressures in financial data services. Analysts maintain 73% buy ratings, citing undervaluation relative to growth prospects, but investors should monitor execution on integration of recent acquisitions and interest rate impacts on financing costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
